While many desire a simple model, this may have a range of complications which give rise to
substantial litigation over the next 10 years.
In many cases, this element is the easiest for the plaintiff to prove, but in others there may be
substantial litigation over whether a duty of care exists.
Not exact matches
Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions, including with respect to the Merger; the
substantial level of government regulation
over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of
litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential
litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing, including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.
Perinatal events can result in associated longer term health and broader societal costs, as shown by the size of damages paid in obstetric
litigation cases, which represent a
substantial cost to the NHS.27 Follow - up
over weeks or longer to monitor recovery, or a future assessment of the outcomes for mothers and babies at a later date, would act as a vehicle for estimating costs and consequences beyond the perinatal period and shed more light on long term cost effectiveness.
As a Partner in the firm's
Litigation Division for
over 25 years, John dealt with a wide range of
substantial commercial disputes, with experience of resolving cases in the Courts, by arbitration and through ADR.
Over the past 35 years, Ben has developed
substantial litigation and subject matter expertise defending licensed professionals, entrepreneurs, and senior executives in essentially every type of business dispute involving securities, malpractice, trusts, and employment issues.
Jack has
over twenty years of experience in numerous types of commercial
litigation matters, with
substantial representations of clients in many matters involving environmental
litigation, including five trials pursuant to the Comprehensive Environmental Response, Compensation and Liability Act, significant architectural, engineering and construction disputes, business acquisition and transactional disputes, including takeover / merger and acquisition
litigation, claims under purchase and sales and indemnity contracts, securities law
litigation, insurance coverage on behalf of the insured, and legal issues relating to medical records release and copying.
«Reining in Remedies in Patent
Litigation: Three (Increasingly Immodest) Proposals» proposes that injunctions be unavailable
over FRAND - pledged SEPs, advocates apportionment of the disgorgement of an infringer's profits that a design patent holder can seek (this approach would have taken care of a
substantial part of the damages issue in Apple v. Samsung, for example), and finally — which is the most ambitious part but makes a lot of sense to me — elaborates in the form of a «thought experiment» on an idea Judge Posner tossed out a few month ago: for a «wide swath of U.S. patent cases» it might be preferable to avoid juries.
The man was also awarded
substantial costs of the
litigation of
over $ 180,000.
By interacting with an attorney often,
over time the client dramatically reduces
litigation risk, which yields
substantial cost savings.
He has acted on transactions in
over 50 countries with
substantial experience in
litigation and dispute resolution.